Overview

In this video, Prof. Gil Yosipovitch reviews key skin and itch data supporting the efficacy
of Ebglyss® (lebrikizumab), an IL-13 inhibitor, in moderate-to-severe atopic dermatitis.
He outlines the standard endpoints used in studies of IL-13 and IL-13/4 inhibitors and
explains the concept of a stable response — defined as no or minimal fluctuations with
treatment — across key measures of skin clearance and itch relief in moderate-to-severe
AD.

This Class for

Clinical Pharmacy
Pharmacy
Physician
Resident / Fellow

What I will learn?

● Review the key skin and itch efficacy data for lebrikizumab in
moderate-to-severe atopic dermatitis.
● Describe the standard endpoints used in studies of IL-13 and IL-13/4
inhibitors in moderate-to-severe atopic dermatitis.
● Define a stable response as no or minimal fluctuations with treatment.
● Explain the clinical relevance of maintaining a stable response in
moderate-to-severe atopic dermatitis.

Disclaimer

This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: [email protected]

24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

For Lilly product information: email: [email protected]

For further information, please contact:

Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]

PP-LK-SA-0196

Content